Cystic Fibrosis Foundation Therapeutics Extends Partnership with Proteostasis Therapeutics To Target Delta F508 Treatment

Cystic Fibrosis Foundation Therapeutics Extends Partnership with Proteostasis Therapeutics To Target Delta F508 Treatment
0
(0)

Cystic Fibrosis FoundationThe Cystic Fibrosis Foundation describes CF as a genetically-acquired chronic disease that impacts the lungs and gastrointestinal tract, causing these body systems to produce abnormally thick, and viscid mucus that has the tendency to consolidate in the lungs and block the secretion of pancreatic enzymes, resulting in malabsorption. Today, about 30,000 American children and adults, and over 70,000 people are affected all over the globe. While treatment for the disease has made tremendous strides over the past few decades, cystic fibrosis is still a deadly disease that affects most patients from early childhood and dramatically affects quality of life and lifespan.

In order to further accelerate research and development of viable, effective CF therapies, Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a subdivision of the Cystic Fibrosis Foundation, recently revealed that they will be prolonging the grant for their partnership with Proteostasis Therapeutics, Inc., which is geared towards developing state-of-the-art treatments for the most prevalent form of cystic fibrosis, Delta F508.

Delta F508 research by Proteostasis TherapeuticsProteostasis Therapeutics will carry on with their dedication to research and development for the Delta F508 form of CF, particularly on the molecular process behind fixing the faulty intracellular CFTR protein that underlies the disease in order to return it to proper functioning.

When the Delta F508 variation is considered, the faulty protein in CFTR does not proceed to the correct site on the cell’s exterior, causing an obstruction in the movement of secretions into the airways. It is estimated that about 90% of people living with cystic fibrosis carry at the least one copy of the this mutation. Thus, the funding and research effort behind this particular project could bear out wide-ranging positive outcomes throughout the entire cystic fibrosis patient population.

[adrotate group=”1″]

Aside from the partnership with Proteostasis, the CFFT is putting money into a series of future treatment modalities designed to combat cystic fibrosis using a multitude of approaches, including partnering with Pfizer, Genzyme and Vertex to boost research and development of breakthrough drugs.

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Latest Posts
  • lung transplant guidelines
  • WVU CFF accreditation
  • Vertex Foundation matching gift program

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?